Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Goldman Sachs Group (NY:GS)

707.75 +16.94 (+2.45%)
Official Closing Price Updated: 4:10 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Goldman Sachs Group

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Corporate America's Best Earnings In 3 Years: Will Tariffs End Wall Street's Honeymoon?
Corporate America cheers strong earnings season in 2024, but trade uncertainty looms as Trump's tariff plans dominate earnings calls. 
Via Benzinga
Topics Government World Trade
I'd Still Buy Alphabet Stock Despite the Stumble Over Q4 Cloud Growth. Here's Why.
Too many investors are looking right past a couple of obscured bullish details regarding the company's future. 
Via The Motley Fool
Intuit's AI, Market Expansion Position It For Long-Term Growth: Goldman Sachs
Goldman Sachs analyst Kash Rangan maintains a Buy rating on Intuit Inc (NASDAQ:INTU) with an $800 price target. Despite intensifying competition in the lower tax market, Rangan sees Intuit capturing... 
Via Benzinga
Topics Artificial Intelligence
Former Veep Al Gore Is Renting Out His Suburban DC Home for $9,000/month. Not That He Needs the Money. He's Worth $300M
Via Benzinga
Bank Stocks Rally After Federal Reserve Releases 2025 Stress Test Parameters With Smaller Shocks
According to the new scenario, the U.S. unemployment rate will rise nearly 5.9 percentage points to a peak of 10%. 
Via Stocktwits
Topics Economy
Looking At Goldman Sachs Gr's Recent Unusual Options Activity
Via Benzinga
Check Out What Whales Are Doing With Goldman Sachs Gr
Via Benzinga
Peter Schiff Slams Fed's Stress Tests For Ignoring Stagflation Risks: 'They Know No Major Bank Could Survive It'
Renowned economist Peter Schiff has expressed criticism of the Federal Reserve's recent bank stress tests, highlighting the lack of preparation for a potential stagflation scenario. 
Via Benzinga
Topics Economy
Fed Eases Bank Stress Tests, Drops Climate Risks: Financial Stocks Hit Record Highs
Fed dials back regulatory burden on major US banks, ending climate stress test and rolling out more favorable 2025 scenario. Relief for Goldman Sachs and Morgan Stanley expected. 
Via Benzinga
Topics Economy
Institutional Investors Continue to Consider ESG Despite the Ongoing Backlash
Via Investor Brand Network
Topics Government
CURE ALZHEIMER’S FUND APPOINTS THREE NEW MEMBERS TO ITS BOARD OF DIRECTORS
Mary Greenhill Cagliero, Mark Faggiano and Kumar Mahadeva Bring Deep Expertise to Board Roles 
Via News Direct
Analysts Defend Merck Amid Investor Concerns Over Weak Guidance
Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a lower-than-expected 2025 outlook. 
Via Benzinga
Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday?
It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged... 
Via Benzinga
Topics Stocks
IBM Story Is Underappreciated, Goldman Sachs Says Stock Can Re-Rate Higher
Goldman Sachs analyst maintains Buy rating on IBM, citing potential for growth in TMT sector and strong Software revenue outlook. 
Via Benzinga
Uber Stock Tumbles, Analyst Lists Autonomous Vehicles As 'Key Risk'
Goldman Sachs analyst maintains Buy rating on Uber Technologies Inc with $96 price target. Q4 gross bookings beat estimates with strong Mobility & Delivery segments. Adjusted EBITDA & EPS in line with... 
Via Benzinga
3 Must-Have ETFs Set to Dominate This Quarter
There are three areas in the market that could clearly command a rotation in the coming quarter, backed by economic tailwinds and themes. 
Via MarketBeat
Topics Bonds ETFs Economy
What Drives Billionaire Masayoshi Son?
The man behind SoftBank has now teamed up with OpenAI to invest up to $500 billion in American AI infrastructure over the next four years. 
Via The Motley Fool
Topics Artificial Intelligence
1 Vanguard Index Fund May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst
Via The Motley Fool
Topics Stocks
These Were the 5 Top-Performing Stocks in the Dow Jones Industrial Average in January 2025
Via The Motley Fool
Topics Stocks
PepsiCo Remains Very Well Positioned Despite Near-Term Headwinds: Goldman Sachs
Goldman Sachs analyst Bonnie Herzog reiterated a Buy rating on the shares of PepsiCo with a price forecast of $189.00. 
Via Benzinga
Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
Goldman Sachs and Morgan Stanley are two of the leading investment bankers on Wall Street posting double digit revenue growth in Q4, but which has more upside? 
Via MarketBeat
The Smartest Vanguard ETF to Buy With $1,000 Right Now
Via The Motley Fool
Topics ETFs
4 Banks to Buy Ahead of Trump's Deregulatory Blitz
Fed keeps rates steady, but uncertainty remains. Banking sector could benefit from deregulation. Consider BAC and GS for favorable metrics. 
Via Benzinga
Topics Economy Government
Should You Buy XRP (Ripple) While It Trades Under $3?
Via The Motley Fool
Where Will Nvidia Stock Be in 3 Years?
Via The Motley Fool
3 Reasons to Buy Amazon Stock Like There's No Tomorrow
Via The Motley Fool
Why Brighthouse Financial Stock Blasted Higher This Week
Via The Motley Fool
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure. 
Via Benzinga
Goldman Sachs Forecasts Limited Upside For Occidental & Magnolia: What's Next?
Goldman Sachs downgrades MGY and OXY, reinstates coverage on EXE. MGY's outperformance reflected in current stock price, OXY's leverage a concern. EXE receives Buy rating with potential 18% upside. 
Via Benzinga
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on TikTok. 
Via Benzinga
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.